Last updated: April 26, 2026
Who supplies IOFLUPANE I-123 (I-123 ioflupane) for pharmaceutical and radiopharmacy use?
IOFLUPANE I-123 (Iodine I-123 ioflupane) is supplied through a limited set of radiopharmacy chains and manufacturing/kit supply arrangements tied to regional licensing and radionuclide availability. Commercial supply typically runs through two channels: (1) prepackaged “kit” formulations distributed to qualified radiopharmacies, and (2) direct radiopharmacy fulfillment to end users (imaging centers/hospitals).
What is the product scope for “IOFLUPANE I-123”?
IOFLUPANE I-123 is a diagnostic radiopharmaceutical used for imaging dopamine transporters in the brain (commonly associated with Parkinsonian syndromes assessment). In the US market, it is marketed under the brand name DaTscan (ioflupane I-123 injection), which is supplied via a controlled radiopharmacy network. Supply is therefore more “radiopharmacy-distribution” than “general pharma wholesale.”
Which suppliers actually distribute IOFLUPANE I-123 in practice?
The practical supplier set is:
1) Manufacturing/brand owner of DaTscan and its distribution program
2) Qualified radiopharmacies that prepare/fulfill the dose under applicable regulatory controls
In the US, the brand owner and the associated supply network are tied to the originator product and its US distribution model. The radiopharmacy fulfillment model means “supplier” depends on the delivery point (hospital or imaging center) and the country’s authorized radiopharmacy structure.
US market: DaTscan supply structure
| Supply layer |
Supplier role |
What they provide |
Supply constraint |
| Brand/manufacturing entity |
Originator/marketer |
DaTscan (ioflupane I-123) under the US distribution program |
Brand-specific, limited radiopharmacy handling |
| Authorized radiopharmacies |
Fulfillment |
Prepared I-123 ioflupane dose for administration |
Requires regulatory authorization and radionuclide logistics |
Key brand reference: DaTscan is the commonly referenced commercial form of IOFLUPANE I-123 injection in the US. (Source: FDA drug labeling for DaTscan.)
[1] U.S. Food and Drug Administration (FDA), “DaTscan (ioflupane I 123) injection” label.
Which organizations supply it internationally?
Internationally, IOFLUPANE I-123 availability depends on country licensing (local importers, radiopharmacy networks, and authorization of preparation/dispensing). The same supply mechanics apply: the radionuclide and kit/prepared dose must be handled under radiopharmacy and nuclear medicine controls.
Without country and delivery jurisdiction, the supplier list cannot be stated as a complete and accurate set because regulatory authorization is local and changes over time. In a procurement context, the correct approach is to use the originator product’s distribution program for the jurisdiction, then the authorized radiopharmacies that fulfill to end users.
What procurement inputs determine who can supply it?
For procurement and RFP scoring, IOFLUPANE I-123 is typically gated by:
- Regulatory qualification of the dispensing/preparation site (radiopharmacy authorization for I-123 ioflupane handling and dispensing)
- Chain-of-custody controls for I-123 radionuclide logistics and dose administration timing
- Jurisdiction-specific distribution list for the branded product (DaTscan in the US)
These constraints are embedded in the US label-controlled distribution model and mirror the regulatory framework for radiopharmaceuticals. (Source: FDA labeling for DaTscan.)
[1] U.S. Food and Drug Administration (FDA), “DaTscan (ioflupane I 123) injection” label.
Key Takeaways
- IOFLUPANE I-123 supply is dominated by the originator product distribution program (DaTscan in the US) and authorized radiopharmacy fulfillment, not generic pharmaceutical wholesale.
- The actionable “supplier list” is jurisdiction-specific because radiopharmacy authorization and distribution rights are local and controlled.
- The FDA-labeled product reference for US procurement is DaTscan (ioflupane I-123 injection), which is supplied via a controlled network.
[1]
FAQs
1) Who is the primary supplier for IOFLUPANE I-123 in the US?
The primary branded product supplier is the DaTscan (ioflupane I-123 injection) labelholder under the US distribution program.
[1]
2) Can hospitals buy IOFLUPANE I-123 from general distributors?
In practice, supply runs through authorized radiopharmacies as prepared/dispensed radiopharmaceutical doses under radiopharmacy controls.
[1]
3) Is IOFLUPANE I-123 sold as a standard kit like typical non-radiopharma injectables?
Procurement is radiopharmacy-driven under the labeled distribution model for the branded product (DaTscan).
[1]
4) Does the supplier change by geography?
Yes. Authorization to dispense and the authorized fulfillment network are jurisdiction-specific, and distribution rights are not uniform across countries.
[1]
5) What is the best way to identify the correct supplier for procurement?
Use the labeled product distribution model for the jurisdiction (US: DaTscan labeling) and then procure through the authorized radiopharmacy fulfillment for your delivery location.
[1]
References
[1] U.S. Food and Drug Administration. (n.d.). DaTscan (ioflupane I 123) injection (prescribing information/label). FDA. https://www.accessdata.fda.gov
